Nuvectis Pharma, Inc. Research and Development Expense
Nuvectis Pharma, Inc. (NVCT) reported Research and Development Expense of $4.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- Nuvectis Pharma, Inc. research and development expense for the quarter ending 2026-06-30 was $4.68M, a 29.64% increase year-over-year.
- Nuvectis Pharma, Inc. research and development expense for the quarter ending 2026-03-31 was $4.11M, a 11.58% increase year-over-year.
- Nuvectis Pharma, Inc. research and development expense for the quarter ending 2025-12-31 was $5.09M, a 13.12% increase year-over-year.
- Nuvectis Pharma, Inc. research and development expense for the quarter ending 2025-09-30 was $5.77M, a 104.82% increase year-over-year.
- Nuvectis Pharma, Inc. research and development expense for fiscal 2025 was $18.15M, a 40.52% increase from fiscal 2024.
- Nuvectis Pharma, Inc. research and development expense for fiscal 2024 was $12.92M, a 16.01% decline from fiscal 2023.
- Nuvectis Pharma, Inc. research and development expense for fiscal 2023 was $15.38M, a 16.28% increase from fiscal 2022.
- Nuvectis Pharma, Inc. research and development expense for fiscal 2022 was $13.23M, a 38.58% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.68M 10-Q · filed 2026-08-04 | $8.79M 10-Q · filed 2026-08-04 | $13.88M derived: sum of 3 quarters · filed 2026-08-04 | $19.65M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $4.11M 10-Q · filed 2026-05-05 | $9.19M derived: sum of 2 quarters · filed 2026-05-05 | $14.97M derived: sum of 3 quarters · filed 2026-05-05 | $18.58M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $10.86M derived: sum of 2 quarters · filed 2026-02-11 | $14.47M derived: sum of 3 quarters · filed 2026-08-04 | $18.15M 10-K · filed 2026-02-11 |
| 2025-09-30 | $5.77M 10-Q · filed 2025-11-04 | $9.39M derived: sum of 2 quarters · filed 2026-08-04 | $13.07M 10-Q · filed 2025-11-04 | $17.56M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.61M 10-Q · filed 2026-08-04 | $7.29M 10-Q · filed 2026-08-04 | $11.79M derived: sum of 3 quarters · filed 2026-08-04 | $14.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.68M 10-Q · filed 2026-05-05 | $8.18M derived: sum of 2 quarters · filed 2026-05-05 | $10.99M derived: sum of 3 quarters · filed 2026-05-05 | $13.94M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $7.32M derived: sum of 2 quarters · filed 2026-02-11 | $10.26M derived: sum of 3 quarters · filed 2026-02-11 | $12.92M 10-K · filed 2026-02-11 |
| 2024-09-30 | $2.82M 10-Q · filed 2025-11-04 | $5.76M derived: sum of 2 quarters · filed 2025-11-04 | $8.42M 10-Q · filed 2025-11-04 | $12.69M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $2.94M 10-Q · filed 2025-08-05 | $5.60M 10-Q · filed 2025-08-05 | $9.87M derived: sum of 3 quarters · filed 2025-08-05 | $14.35M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $2.66M 10-Q · filed 2025-05-06 | $6.92M derived: sum of 2 quarters · filed 2025-05-06 | $11.41M derived: sum of 3 quarters · filed 2025-05-06 | $15.67M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $8.75M derived: sum of 2 quarters · filed 2025-02-25 | $13.01M derived: sum of 3 quarters · filed 2025-02-25 | $15.38M 10-K · filed 2025-02-25 |
| 2023-09-30 | $4.49M 10-Q · filed 2024-11-05 | $8.75M derived: sum of 2 quarters · filed 2024-11-05 | $11.12M 10-Q · filed 2024-11-05 | $15.51M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $4.26M 10-Q · filed 2024-08-06 | $6.63M 10-Q · filed 2024-08-06 | $11.03M derived: sum of 3 quarters · filed 2024-08-06 | $15.55M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $2.37M 10-Q · filed 2024-05-07 | $6.76M derived: sum of 2 quarters · filed 2024-05-07 | $11.28M derived: sum of 3 quarters · filed 2024-05-07 | $13.79M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $8.92M derived: sum of 2 quarters · filed 2024-03-05 | $11.42M derived: sum of 3 quarters · filed 2024-03-05 | $13.23M 10-K · filed 2024-03-05 |
| 2022-09-30 | $4.52M 10-Q · filed 2023-11-08 | $7.03M derived: sum of 2 quarters · filed 2023-11-08 | $8.83M 10-Q · filed 2023-11-08 | $9.97M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $2.50M 10-Q · filed 2023-08-09 | $4.31M 10-Q · filed 2023-08-09 | $5.45M derived: sum of 3 quarters · filed 2023-08-09 | $9.61M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.80M 10-Q · filed 2023-05-10 | $2.95M derived: sum of 2 quarters · filed 2023-05-10 | $7.11M derived: sum of 3 quarters · filed 2023-05-10 | $11.35M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $5.30M derived: sum of 2 quarters · filed 2023-03-08 | $9.54M derived: sum of 3 quarters · filed 2023-03-08 | $9.54M 10-K · filed 2023-03-08 |
| 2021-09-30 | $4.16M 10-Q · filed 2022-11-08 | $8.40M derived: sum of 2 quarters · filed 2022-11-08 | $8.40M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $4.25M 10-Q · filed 2022-08-10 | $4.25M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |